                         SEQUENCE LISTING

<110>  Fenstermaker, Robert A
       Ciesielski, Michael J
        
<120>  SURVIVIN PEPTIDES AS CANCER VACCINES

<130>  003551.00331

<150>  60/961,206
<151>  2007-07-19

<160>  20    

<170>  PatentIn version 3.4

<210>  1
<211>  142
<212>  PRT
<213>  human

<400>  1

Met Gly Ala Pro Thr Leu Pro Pro Ala Trp Gln Pro Phe Leu Lys Asp 
1               5                   10                  15      


His Arg Ile Ser Thr Phe Lys Asn Trp Pro Phe Leu Glu Gly Cys Ala 
            20                  25                  30          


Cys Thr Pro Glu Arg Met Ala Glu Ala Gly Phe Ile His Cys Pro Thr 
        35                  40                  45              


Glu Asn Glu Pro Asp Leu Ala Gln Cys Phe Phe Cys Phe Lys Glu Leu 
    50                  55                  60                  


Glu Gly Trp Glu Pro Asp Asp Asp Pro Ile Glu Glu His Lys Lys His 
65                  70                  75                  80  


Ser Ser Gly Cys Ala Phe Leu Ser Val Lys Lys Gln Phe Glu Glu Leu 
                85                  90                  95      


Thr Leu Gly Glu Phe Leu Lys Leu Asp Arg Glu Arg Ala Lys Asn Lys 
            100                 105                 110         


Ile Ala Lys Glu Thr Asn Asn Lys Lys Lys Glu Phe Glu Glu Thr Ala 
        115                 120                 125             


Lys Lys Val Arg Arg Ala Ile Glu Gln Leu Ala Ala Met Asp 
    130                 135                 140         


<210>  2
<211>  140
<212>  PRT
<213>  mouse

<400>  2

Met Gly Ala Pro Ala Leu Pro Gln Ile Trp Gln Leu Tyr Leu Lys Asn 
1               5                   10                  15      


Tyr Arg Ile Ala Thr Phe Lys Asn Trp Pro Phe Leu Glu Asp Cys Ala 
            20                  25                  30          


Cys Thr Pro Glu Arg Met Ala Glu Ala Gly Phe Ile His Cys Pro Thr 
        35                  40                  45              


Glu Asn Glu Pro Asp Leu Ala Gln Cys Phe Phe Cys Phe Lys Glu Leu 
    50                  55                  60                  


Glu Gly Trp Glu Pro Asp Asp Asn Pro Ile Glu Glu His Arg Lys His 
65                  70                  75                  80  


Ser Pro Gly Cys Ala Phe Leu Thr Val Lys Lys Gln Met Glu Glu Leu 
                85                  90                  95      


Thr Val Ser Glu Phe Leu Lys Leu Asp Arg Gln Arg Ala Lys Asn Lys 
            100                 105                 110         


Ile Ala Lys Glu Thr Asn Asn Lys Gln Lys Glu Phe Glu Glu Thr Ala 
        115                 120                 125             


Lys Thr Thr Arg Gln Ser Ile Glu Gln Leu Ala Ala 
    130                 135                 140 


<210>  3
<211>  23
<212>  PRT
<213>  human

<400>  3

Glu Asn Glu Pro Asp Leu Ala Gln Cys Phe Phe Cys Phe Lys Glu Leu 
1               5                   10                  15      


Glu Gly Trp Glu Pro Asp Asp 
            20              


<210>  4
<211>  23
<212>  PRT
<213>  artificial

<220>
<223>  wild type survivin amino acids 49-71 with C to M change at amino 
       acid position 57

<400>  4

Glu Asn Glu Pro Asp Leu Ala Gln Met Phe Phe Cys Phe Lys Glu Leu 
1               5                   10                  15      


Glu Gly Trp Glu Pro Asp Asp 
            20              


<210>  5
<211>  6
<212>  PRT
<213>  artificial

<220>
<223>  survivin vaccine core epitope C to M change at amino acid 57 of 
       full length survivin

<400>  5

Gln Met Phe Phe Cys Phe 
1               5       


<210>  6
<211>  15
<212>  PRT
<213>  artificial

<220>
<223>  survivin amino acids 53-67 with C to M change at position 57

<400>  6

Asp Leu Ala Gln Met Phe Phe Cys Phe Lys Glu Leu Glu Gly Trp 
1               5                   10                  15  


<210>  7
<211>  8
<212>  PRT
<213>  human

<400>  7

Ser Ile Ile Asn Phe Glu Lys Leu 
1               5               


<210>  8
<211>  8
<212>  PRT
<213>  human

<400>  8

Ala Trp Gln Pro Phe Leu Lys Asp 
1               5               


<210>  9
<211>  8
<212>  PRT
<213>  human

<400>  9

Arg Ile Ser Thr Phe Lys Asn Trp 
1               5               


<210>  10
<211>  8
<212>  PRT
<213>  human

<400>  10

Ala Glu Ala Gly Phe Ile His Cys 
1               5               


<210>  11
<211>  8
<212>  PRT
<213>  human

<400>  11

Cys Phe Phe Cys Phe Lys Glu Leu 
1               5               


<210>  12
<211>  8
<212>  PRT
<213>  human

<400>  12

Ser Gly Cys Ala Phe Leu Ser Val 
1               5               


<210>  13
<211>  8
<212>  PRT
<213>  artificial

<220>
<223>  SVN-L82 S to L change

<400>  13

Leu Gly Cys Ala Phe Leu Ser Val 
1               5               


<210>  14
<211>  7
<212>  PRT
<213>  human

<400>  14

Thr Leu Gly Glu Phe Leu Lys 
1               5           


<210>  15
<211>  10
<212>  PRT
<213>  artificial

<220>
<223>  C to M change at position 57

<400>  15

Ala Gln Met Phe Phe Cys Phe Lys Glu Leu 
1               5                   10  


<210>  16
<211>  9
<212>  PRT
<213>  artificial

<220>
<223>  C to M change at position 57

<400>  16

Gln Met Phe Phe Cys Phe Lys Glu Leu 
1               5                   


<210>  17
<211>  8
<212>  PRT
<213>  artificial

<220>
<223>  SVN-57-64 with C to M change at position 57

<400>  17

Met Phe Phe Cys Phe Lys Glu Leu 
1               5               


<210>  18
<211>  15
<212>  PRT
<213>  human

<400>  18

Asp Leu Ala Gln Cys Phe Phe Cys Phe Lys Glu Leu Glu Gly Trp 
1               5                   10                  15  


<210>  19
<211>  10
<212>  PRT
<213>  human

<400>  19

Ala Gln Cys Phe Phe Cys Phe Lys Glu Leu 
1               5                   10  


<210>  20
<211>  9
<212>  PRT
<213>  human

<400>  20

Gln Cys Phe Phe Cys Phe Lys Glu Leu 
1               5                   


